Verdoodt F, et al. - Given that preclinical studies suggest that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) may improve survival of ovarian cancer, researchers assessed the link between non-aspirin NSAID use and ovarian cancer mortality. This study included all women in Denmark with a first diagnosis of epithelial ovarian cancer between 2000 and 2012. Using nationwide registries, data on drug use, mortality outcomes, and potential confounding factors were gathered. The link was determined using Cox regression models. Findings revealed no impact of any postdiagnosis use of non-aspirin NSAIDs on ovarian cancer mortality overall. However, they found that in patients with serous ovarian cancer, more intensive use was associated with improved survival.